Cargando…

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy

Cardiac abnormalities such as left ventricular hypertrophy, left ventricular dilation, and pulmonary hypertension in sickle cell anemia have been previously described. Hydroxyurea, a disease-modifying therapy for sickle cell anemia, has been used for several decades. Longitudinal assessment of echoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhar, Arushi, Leung, Tung Ming, Appiah-Kubi, Abena, Gruber, Dorota, Aygun, Banu, Serigano, Olivia, Mitchell, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579269/ https://www.ncbi.nlm.nih.gov/pubmed/34529023 http://dx.doi.org/10.1182/bloodadvances.2021005076

Ejemplares similares

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2022)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
por: Henrici, Ryan C., et al.
Publicado: (2021)

Mental Health Assessment of Youth with Sickle Cell Disease and Their Primary Caretakers: Baseline Depression and COVID-19 Pandemic-Associated Psychosocial Stress in a Multi-Site Study
por: Green, Nancy S., et al.
Publicado: (2020)

Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial
por: Namazzi, Ruth, et al.
Publicado: (2023)

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
por: Meier, Emily R., et al.
Publicado: (2020)

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia
por: Sheehan, Vivien A., et al.
Publicado: (2014)

Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
por: Nottage, Kerri A., et al.
Publicado: (2013)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
por: Minniti, Caterina P., et al.
Publicado: (2021)

Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
por: Adamkiewicz, Thomas V., et al.
Publicado: (2023)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Metformin for treatment of cytopenias in children and young adults with Fanconi anemia
por: Pollard, Jessica A., et al.
Publicado: (2022)

Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2021)

Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
por: Jiao, Boshen, et al.
Publicado: (2023)

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study
por: Heeney, Matthew M., et al.
Publicado: (2022)

Early diagnosis of sickle cell disease at birth hospitals and vaccination centers in Angola using point-of-care tests
por: Olaniyan, Halimat S., et al.
Publicado: (2023)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia
por: de Boer, Esther C. W., et al.
Publicado: (2023)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia
por: Delgadinho, Mariana, et al.
Publicado: (2022)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia
por: Vinhaes, Caian L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b5ntiofn2mksntmkhs6qfr658u